OncoMethylome Presents Promising Results of Colorectal Cancer Screening Program at Digestive Disease Week Conference
(Thomson Reuters ONE) -
DURHAM, NC, and LIEGE, BELGIUM - May 3, 2010, 8:00 CET - OncoMethylome Sciences
(Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA), a leading molecular
diagnostics company, presented an update on its blood-based colorectal screening
test and promising preliminary results of the performance of its proprietary DNA
methylation biomarker in combination with stool-based testing at the Annual
Digestive Disease Week (DDW) Conference. The presentation was part of an
overview of the company's colorectal cancer screening program given at the World
Organization of Digestive Endoscopy (OMED) Colorectal Cancer Screening Committee
Meeting, which is being held as part of DDW. DDW is the world's largest annual
gathering of physicians and researchers in the fields of endoscopy,
gastroenterology, hepatology and gastrointestinal surgery.
"The combination of a DNA methylation biomarker with a commercially available
fecal immunochemical test is showing excellent potential as a non-invasive and
accurate screening test for colorectal cancer. In our study, the sensitivity and
specificity of the combined test are both over 90% while also detecting a high
percentage of early stage cancers" said Prof. Gerrit Meijer, from the VU
University Medical Center in Amsterdam (VUMC), whose team conducted the latest
case-control study using stool samples.
Dr. Jan Groen, Chief Executive Officer of OncoMethylome, said, "Our most recent
case-control study in blood samples confirmed earlier results presented in
September 2009 and we are delighted with the promising preliminary results in
stool samples reported by the group at VUMC that constitute an independent
validation of the clinical relevance of our proprietary methylation biomarker in
colon cancer screening."
About OncoMethylome Sciences
OncoMethylome Sciences is a leading molecular diagnostics company that
commercializes and develops cancer-screening tests to assist physicians in
detecting and treating cancer early. The company's tests are based on
proprietary gene methylation technology invented at Johns Hopkins University and
are designed to help the physician accurately detect early stages of cancer
development, predict a patient's response to drug therapy, and predict the
likelihood of cancer recurrence. OncoMethylome Sciences collaborates with
leading cancer research centers, such as Johns Hopkins, in Baltimore, MD, and
has a number of commercial and collaborative partnerships with LabCorp,
Schering-Plough, GlaxoSmithKline Biologicals, Millipore Corporation's BioScience
Division, Merck KGaA and Qiagen.
For more information:
Dr. Jan Groen
President & CEO
+32 4.364.20.70 office
IR(at)oncomethylome.com
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of OncoMethylome and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the Company's
control, and may turn out to be materially different.
[HUG#1410928]
2010-5-3 DDW Conference ENG: http://hugin.info/137314/R/1410928/363275.pdf
Unternehmensinformation / Kurzprofil:
Datum: 03.05.2010 - 08:00 Uhr
Sprache: Deutsch
News-ID 20130
Anzahl Zeichen: 0
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 357 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OncoMethylome Presents Promising Results of Colorectal Cancer Screening Program at Digestive Disease Week Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
OncoMethylome Sciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
